3D Printed Drugs Market Sets New Record, Projected at USD 522 million by 2030 | CAGR of 6.5%

December 13, 2023 11:13 PM AEDT | By EIN Presswire
 3D Printed Drugs Market Sets New Record, Projected at USD 522 million by 2030 | CAGR of 6.5%
Image source: EIN Presswire

Surge in demand for instantaneous soluble drugs that can disperse easily in the mouth is the major factor that drives the growth of the global market.

PORTLAND, OREGON, UNITED STATES, December 13, 2023 /EINPresswire.com/ -- According to a new report published by Allied Market Research, titled, "3D Printed Drugs Market by Forecast Scenario Analysis: Global Opportunity Analysis and Industry Forecast, 2022-2030", Spritam is the only 3D printed drug available in the market since 2016 to treat epilepsy. The potential market for other 3D printed drugs (moderate growth scenario) is estimated to be USD 278 million in 2020, and would reach USD 522 million by 2030, growing at a CAGR of 6.5% from 2020 to 2030. U.S. market holds the highest market share in 2020.

The report provides a detailed analysis of the top investment pockets, top winning strategies, drivers & opportunities, market size & estimations, competitive landscape, and evolving market trends. The market study is a helpful source of information for the frontrunners, new entrants, investors, and shareholders in crafting strategies for the future and heightening their position in the market.

𝐖𝐡𝐚𝐭 𝐢𝐬 𝐭𝐡𝐞 𝐅𝐮𝐭𝐮𝐫𝐞 𝐨𝐟 𝟑𝐃 𝐏𝐫𝐢𝐧𝐭𝐢𝐧𝐠 𝐃𝐫𝐮𝐠𝐬 𝐈𝐧 𝐏𝐡𝐚𝐫𝐦𝐚𝐜𝐢𝐞𝐬?

The future of 3D printing drugs in pharmacies is promising, with the potential to revolutionize the way medications are manufactured and delivered to patients. Here are some potential developments and benefits:

✅𝐏𝐞𝐫𝐬𝐨𝐧𝐚𝐥𝐢𝐳𝐚𝐭𝐢𝐨𝐧: 3D printing can be used to create customized dosage forms that are tailored to individual patient needs. This could lead to better treatment outcomes and reduced side effects.
✅𝐎𝐧-𝐃𝐞𝐦𝐚𝐧𝐝 𝐌𝐚𝐧𝐮𝐟𝐚𝐜𝐭𝐮𝐫𝐢𝐧𝐠: 3D printing allows for the rapid production of small batches of drugs, which could improve supply chain efficiency and reduce waste.
✅𝐍𝐨𝐯𝐞𝐥 𝐃𝐫𝐮𝐠 𝐃𝐞𝐥𝐢𝐯𝐞𝐫𝐲 𝐒𝐲𝐬𝐭𝐞𝐦𝐬: 3D printing enables the creation of complex drug delivery systems, such as implants and microneedles, which can improve drug efficacy and patient compliance.
✅𝐈𝐦𝐩𝐫𝐨𝐯𝐞𝐝 𝐅𝐨𝐫𝐦𝐮𝐥𝐚𝐭𝐢𝐨𝐧𝐬: 3D printing can be used to create drug formulations with improved solubility, bioavailability, and stability, which can enhance drug efficacy and reduce the need for preservatives and other additives.
✅𝐂𝐨𝐬𝐭 𝐒𝐚𝐯𝐢𝐧𝐠𝐬: By enabling more efficient drug manufacturing and reducing waste, 3D printing has the potential to lower the cost of medications.

𝐒𝐚𝐦𝐩𝐥𝐞 𝐏𝐃𝐅 𝐑𝐞𝐩𝐨𝐫𝐭 𝐰𝐢𝐭𝐡 𝐆𝐫𝐚𝐩𝐡𝐬 𝐚𝐧𝐝 𝐅𝐢𝐠𝐮𝐫𝐞𝐬 𝐇𝐞𝐫𝐞: https://www.alliedmarketresearch.com/request-sample/4508

Rise in the number of individuals suffering from different chronic conditions, increase in geriatric population, and surge in the number of traumatic accidents drive the global ambulance services market. Based on region, North America held the largest share in 2021, contributing to nearly two-fifths of the global ambulance service market share.

𝟑𝐃-𝐩𝐫𝐢𝐧𝐭𝐞𝐝 𝐃𝐫𝐮𝐠𝐬 𝐜𝐨𝐦𝐩𝐚𝐧𝐢𝐞𝐬

✅Aprecia Pharmaceuticals - Aprecia was the first company to gain FDA approval for a 3D-printed drug, Spritam, which is used to treat epilepsy.
✅FabRx - FabRx is a UK-based company that specializes in 3D printing of personalized medicines, including drug-loaded filaments, pellets, and tablets.
✅GlaxoSmithKline - GSK has been developing 3D-printed medicines using its proprietary "Inkjet" technology, which allows for the printing of drugs with precise dosages and formulations.
✅Merck & Co. - Merck has been exploring the use of 3D printing in drug development, including the production of personalized dosages and drug delivery systems.
✅Sanofi - Sanofi has partnered with the 3D printing company Aprecia to develop new formulations of medications using 3D printing technology.

𝟑𝐃 𝐏𝐫𝐢𝐧𝐭𝐞𝐝 𝐃𝐫𝐮𝐠𝐬 𝐌𝐚𝐫𝐤𝐞𝐭 𝐬𝐞𝐠𝐦𝐞𝐧𝐭𝐚𝐭𝐢𝐨𝐧

The 3D printed drugs market can be segmented in various ways based on different criteria, including:

✅By Technology: The market can be segmented based on the different 3D printing technologies used to produce drugs, such as powder bed fusion, binder jetting, and fused filament fabrication.
✅By Application: The market can be segmented based on the different therapeutic areas in which 3D-printed drugs can be used, such as neurology, oncology, cardiology, and others.
✅By End-user: The market can be segmented based on the different end-users of 3D-printed drugs, such as hospitals, research institutes, and pharmaceutical companies.
✅By Type: The market can also be segmented based on the type of 3D-printed drugs, such as oral tablets, capsules, implants, and others.

Europe is estimated to account for four-sevenths share in 2020, and is expected to dominate the market throughout the forecast period, due to presence of well-established healthcare systems and increase in prevalence of dysphagia. In addition, increase in adoption of 3D printed drugs is anticipated to provide new growth opportunities for the key players in the European market. However, Asia-Pacific is projected to grow at the highest growth rate during the analysis period, owing to increase in healthcare expenditure, rise in awareness related to 3D printing technique, presence of large patient pool, and developments in healthcare infrastructure.

Purchase the Report: https://www.alliedmarketresearch.com/purchase-enquiry/4508

Key Benefits For Stakeholders

• This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the 3D Printed Drugs Market analysis from 2020 to 2030 to identify the prevailing 3D Printed Drugs Market opportunities.
• The market research is offered along with information related to key drivers, restraints, and opportunities.
• Porter’s five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
• In-depth analysis of the molecular diagnostics market segmentation assists to determine the prevailing market opportunities.
• Major countries in each region are mapped according to their revenue contribution to the global market.
• Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
• The report includes the analysis of the regional as well as global 3D Printed Drugs Market trends, key players, market segments, application areas, and market growth strategies.

Our Market Research Solution Provides You Answer to Below Mentioned Question:

• Which are the driving factors responsible for the growth of market?
• Which are the roadblock factors of this market?
• What are the new opportunities, by which market will grow in coming years?
• What are the trends of this market?
• Which are main factors responsible for new product launch?
• How big is the global & regional market in terms of revenue, sales and production?
• How far will the market grow in forecast period in terms of revenue, sales and production?
• Which region is dominating the global market and what are the market shares of each region in the overall market in 2022?
• How will each segment grow over the forecast period and how much revenue will these segments account for in 2030?
• Which region has more opportunities?

By Region Outlook

• North America
(U.S., Canada, Mexico)
• Europe
(Germany, France, UK, Italy, Spain, Rest of Europe)
• Asia-Pacific
(Japan, China, India, Rest of Asia-Pacific)
• LAMEA
(Brazil, Saudi Arabia, South Africa, Rest of LAMEA)

Contact Details:

David Correa
USA/Canada (Toll Free): +1-800-792-5285, +1-503-894-6022
[email protected]

About Us

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of “Market Research Reports” and “Business Intelligence Solutions.” AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

David Correa
Allied Analytics LLP
+ +1 800-792-5285
email us here
Visit us on social media:
Facebook
Twitter
LinkedIn


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.


AU_advertise

Advertise your brand on Kalkine Media

Sponsored Articles


Investing Ideas

Previous Next
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.